bpc 157 randomized controlled trial 2025 What are Peptides? Regeneration or Risk? A Narrative

The data is striking: in a Phase 2 trial published in the New England Journal of Medicine, the highest doses produced an average ~24% body-weight reduction at 11 months more than any currently approved weight-loss drug (American Diabetes Association)

Histopathologic correlates of serum amylase activity in acute experimental pancreatitis

Discontinuing peptide therapy often leads to weight regain

Mitochondrial Dysfunction in Type 2 Diabetes and Obesity Well established data demonstrate that mitochondrial dysfunction, particularly as it relates to the processes of oxidative phosphorylation, is contributory to the development of encephalomyopathy, mitochondrial myopathy, and several age-related disorders that include neurodegenerative diseases, the metabolic syndrome, and diabetes